- Global Pharma News & Resources

HDAC Inhibitor Pipeline Insights, 2019 - Developmental Stage, Product Type, Molecule Type, and Administration Route -

The "HDAC Inhibitor -Pipeline Insight, 2019" drug pipelines has been added to's offering.

HDAC Inhibitor - Pipeline Insight, 2019 report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across HDAC Inhibitor development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for HDAC Inhibitor - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for HDAC Inhibitor

The report assesses the active HDAC Inhibitor pipeline products by developmental stage, product type, molecule type, and administration route.

Scope of the report

  • Provides a snapshot of the therapeutics pipeline activity for HDAC Inhibitor
  • Features the HDAC Inhibitor pipeline across the complete product development cycle including all clinical and non-clinical stages
  • Offers detailed therapeutic product profiles of HDAC Inhibitor with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information
  • Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
  • Coverage of dormant and discontinued pipeline projects across HDAC Inhibitor

Companies Mentioned (Partial List)

  • 4SC
  • Acetylon
  • Acetylon Pharmaceuticals
  • Arno Therapeutics
  • BioMarin Pharmaceutical Inc.
  • Celgene
  • Cellceutix Corporation
  • Celleron Therapeutics Ltd
  • Cetya Therapeutics
  • Chipscreen Biosciences, Ltd.
  • Chong Kun Dang pharmaceutical Corp.
  • Chroma Therapeutics
  • Curis
  • EDO GmbH
  • EpiGen

For more information about this drug pipelines report visit

View source version on

Editor Details

Last Updated: 25-Jan-2019